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Abstract
Purpose This analysis from an observational study of
clinical practice describes the impact of febrile neutropenia
(FN) on chemotherapy delivery and hospitalizations.
Methods Adults with diffuse large B-cell lymphoma
(DLBCL) scheduled to receive ≥3c y c l e so f2 -o r3 - w e e k l y
CHOP with rituximab (R-CHOP-14/21) were eligible.
Primary outcome was incidence of FN.
Results FN data were available for 409 patients receiving
R-CHOP-14 and 702 patients receiving R-CHOP-21. FN
incidence was R-CHOP-14, 20% (81/409) and R-CHOP-
21, 19% (133/702). Rates of primary prophylaxis with
granulocyte-colony stimulating factor were R-CHOP-14,
84% (345/409) and R-CHOP-21, 36% (252/702). A large
number of patients experienced their first FN episode in
cycle 1 (R-CHOP-14, 24/81 [30%]; R-CHOP-21, 63/133
[47%]). Multiple risk factors (≥2) for FN were more
frequent in patients experiencing FN than in patients not
experiencing FN (R-CHOP-14, 60/81 [74%] versus 179/
328 [55%]; R-CHOP-21, 98/133 [74%] versus 339/569
[60%]). A similar trend was observed for unplanned
hospitalizations (R-CHOP-14, 63/81 [78%] versus 68/328
[21%]; R-CHOP-21, 105/133 [79%] versus 100/569
[18%]). Achievement of chemotherapy relative dose
intensity ≥90% was lower among patients experiencing
FN than in patients not experiencing FN (R-CHOP-14,
30/81 [37%] versus 234/328 [71%]; R-CHOP-21, 83/
133 [62%] versus 434/569 [76%]).
Conclusions In patients with DLBCL treated with R-CHOP-
14 or R-CHOP-21, patients with an event of FN were more
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likely to impact chemotherapy delivery and to incur
substantial costs.
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Introduction
In patients with aggressive non-Hodgkin lymphoma (NHL),
reduced chemotherapy delivery has been associated with
impaired outcomes [20]. Survival may be significantly
decreased when such patients receive 3-weekly CHOP
(cyclophosphamide, doxorubicin, vincristine, prednisolone;
CHOP-21) chemotherapy delivered at less than 90% of the
planned relative dose intensity (RDI) [3, 15]. Moreover,
due to myelotoxicity, patients receiving CHOP regimens
often experience febrile neutropenia (FN), which can
impede and reduce chemotherapy delivery, particularly if
hospitalization is required [16].
International guidelines recommend primary prophylaxis
with granulocyte-colony stimulating factor (PP G-CSF) for
patients scheduled to receive CHOP-21 and rituximab (R-
CHOP-21) who are assessed as being at high risk (≥20%)
of experiencing FN and to allow effective delivery of 2-
weekly regimens such as R-CHOP-14 [1, 18]. The
myelotoxic potential of the planned chemotherapy regimen
and known patient risk factors for FN, such as older age
(≥65 years), advanced disease, poor performance status,
bone marrow involvement, baseline hemoglobin <12 g/dL
and co-morbidities, should be considered when assessing
FN risk for individual patients [1, 12, 14, 18]. This analysis
from an observational study of European and Australian
clinical practice describes the impact of FN on chemother-
apy delivery and hospitalizations in patients with diffuse
large B-cell lymphoma (DLBCL) receiving R-CHOP
regimens.
Methods
IMPACT NHL is an international, retrospective and
prospective, observational, multicenter study conducted to
evaluate FN risk assessment and G-CSF prophylaxis use in
clinical practice among patients with NHL receiving CHOP.
The study enrolled adults (≥18 years) with any histological
type of NHL, for whom at least three cycles of CHOP-14 or
CHOP-21, with or without rituximab, were planned. The
design of this study has been described elsewhere [7, 17].
The present analysis included a subgroup of patients
with DLBCL who received R-CHOP-14 or R-CHOP-21
and for whom FN data were available. In NHL, DLBCL
represents the most common histological tumor type
routinely treated with R-CHOP regimens.
FN was defined as:
& A single oral temperature ≥38.3°C or
& A temperature ≥38.0°C for ≥1 h with a neutrophil count
of ≤0.5×10
9/L or a neutrophil count ≤1.0×10
9/L which
was predicted to fall below 0.5×10
9/L
The proportion of patients experiencing FN during all
chemotherapy cycles and during cycle 1 was summarized
by R-CHOP regimen. In this report, patients who experi-
enced FN will be referred to as the “FN” group, and
patients who did not experience FN referred to as the “No
FN” group.
G-CSF use was also summarized by R-CHOP regimen.
PP was defined as initiation of G-CSF within days 1–7o f
chemotherapy cycle 1 (or within days 1–11 if chemother-
apy was dosed beyond day 7). Secondary prophylaxis (SP)
was defined as per PP, but with G-CSF initiated in cycles 2
or later.
The proportion of patients experiencing the following
outcome measures was summarized by the R-CHOP
regimen and FN group:
& Chemotherapy dose reductions ≥10% (in cyclophos-
phamide or doxorubicin) in any cycle
& Dose delays >3 days (for patients who received at least
two chemotherapy cycles)
& Proportion of patients achieving chemotherapy RDI≥
90% during all cycles
& Unplanned hospitalizations
RDI was defined as the actual dose intensity achieved by
a patient relative to their planned dose intensity for their
intended chemotherapy schedule (i.e., R-CHOP-14 or R-
CHOP-21) and was calculated as follows: RDI (%)=
actual dose intensity/planned dose intensity; actual dose
intensity=actual dose received for agent (mg/m
2)/actual
total length of chemotherapy for all agents (days), planned
dose intensity=planned total dose for agent (mg/m
2)/
planned length of chemotherapy for all agents (days).
Vincristine, prednisone, and rituximab were excluded
from the calculation of dose reductions and RDI as the
dose intensities delivered for these agents are unlikely
to be affected by neutropenia. An unplanned hospitali-
zation was defined as any unplanned hospitalization
involving an overnight stay.
The 95% exact binomial confidence interval (CI) for the
incidence of chemotherapy delays, dose reductions, RDI,
and unplanned hospitalizations was calculated for each
treatment group. All comparisons between treatment groups
648 Support Care Cancer (2012) 20:647–652were descriptive only; no formal hypothesis testing was
planned.
Results
In total, 1,111 patients with DLBCL treated between 2005
and 2008, and for whom FN data were available, were
included in this analysis. Of these, 409 (37%) received R-
CHOP-14 and 702 (63%) received R-CHOP-21.
Six cycles of chemotherapy were planned in half of all
patients (R-CHOP-14, 222/409 [54%]; R-CHOP-21, 348/
702 [50%]); eight cycles were planned in one third of
patients (R-CHOP-14, 131/409 [32%]; R-CHOP-21: 259/
702 [38%]); three or four cycles were planned in 13% of
patients (R-CHOP-14, 55/409; R-CHOP-21, 88/702). Most
patients completed their planned chemotherapy (R-CHOP-
14, 357/409 [87%]; R-CHOP-21, 603/702 [86%]). Patients
receiving R-CHOP-14 tended to be younger than those
receiving R-CHOP-21 and were less likely to have poor
Table 1 Baseline demographics and disease characteristics
R-CHOP-14 (N=409) R-CHOP-21 (N=702)
FN No FN Overall FN No FN Overall
a
N=81 N=328 N=409 N=133 N=569 N=704
Age in years, mean±SD 61.1±13.1 57.7±15.0 58.4±14.7 65.2±11.8 62.0±14.2 62.6±13.8
Age ≥65 years, n (%) 39 (48) 129 (39) 168 (41) 85 (64) 275 (48) 361 (51)
Female, n (%) 42 (52) 129 (39) 171 (42) 70 (53) 265 (45) 327 (46)
BMI in kg/m
2, mean±SD 25.9±4.4
b 25.4±4.9
c 25.5±4.8 25.5±4.9 25.7±4.4
d 25.7±4.5
ECOG performance status, n (%)
0, 1 68 (84) 304 (93) 372 (91) 100 (75) 489 (86) 591 (84)
2, 3, 4 13 (16) 18 (5) 31 (8) 24 (18) 48 (8) 72 (10)
Missing 0 (0) 6 (2) 6 (1) 9 (7) 32 (6) 41 (6)
Ann Arbor stage, n (%)
III 22 (27) 73 (22) 95 (23) 20 (15) 117 (21) 138 (20)
IV 40 (49) 108 (33) 148 (36) 57 (43) 180 (32) 237 (34)
IPI, n (%)
Low 14 (17) 110 (34) 124 (30) 26 (20) 184 (32) 211 (30)
Intermediate 44 (54) 166 (51) 210 (51) 60 (45) 223 (39) 284 (40)
High 18 (22) 18 (5) 36 (9) 26 (20) 62 (11) 88 (13)
Missing 5 (6) 34 (10) 39 (10) 21 (16) 100 (18) 121 (17)
Bone marrow involvement, n (%) 14 (17) 41 (13) 55 (13) 26 (20) 83 (15) 109 (15)
History of co-morbidities, n (%) 48 (59) 141 (43) 189 (46) 80 (60) 292 (52) 375 (53)
No prior treatment
e, n (%) 72 (89) 299 (91) 371 (91) 122 (92) 510 (90) 634 (90)
Number of risk factors for FN
f, n (%)
0 5 (6) 54 (16) 59 (14) 10 (8) 93 (16) 104 (15)
1 16 (20) 95 (29) 111 (27) 25 (19) 137 (24) 162 (23)
2 23 (28) 84 (26) 107 (26) 22 (17) 148 (26) 170 (24)
3 14 (17) 63 (19) 77 (19) 36 (27) 102(18) 139 (20)
≥4 23 (28) 32 (10) 55 (13) 40 (30) 89 (16) 129 (18)
Known risk factors for FN are italicized
FN febrile neutropenia, BMI body mass index, ECOG Eastern Cooperative Oncology Group, IPI International Prognostic Index
aIncludes two patients for whom FN data were unavailable and who are excluded from other analyses presented
bn=80
cn=327
dn=566
eNo chemotherapy, radiotherapy, or other prior treatment
fRisk factors are age ≥65 years; Ann Arbor stage III or IV; ECOG performance status ≥2; current or continuing cardiovascular, respiratory, renal,
or hepatic/biliary co-morbidities; baseline serum albumin <35 g/L; baseline hemoglobin <12 g/dL; bone marrow involvement
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PP G-CSF was administered in 84% (345/409) of
patients receiving R-CHOP-14 and in 36% (252/702) of
patients receiving R-CHOP-21. Approximately two thirds
of these patients received pegfilgrastim (R-CHOP-14, 226/
345 [66%]; R-CHOP-21, 174/252 [69%]). The remainder
received daily G-CSF, with a mean (±SD) of five daily G-
CSF doses per cycle [R-CHOP-14, 5.23±2.73; R-CHOP-
21, 5.25±1.65]. SP G-CSF was administered in 14% (56/
409) of patients receiving R-CHOP-14 and in 29% (203/
702) of patients receiving R-CHOP-21.
Overall, 20% (81/409) of patients receiving R-CHOP-14
and 19% of patients receiving R-CHOP-21 (133/702)
experienced FN at any time during the study. Median
duration of FN episode was 4.0 days for both regimens (R-
CHOP-14, range 1–20 days; R-CHOP-21, range 1–21 days).
In the R-CHOP-14 group, approximately one third of
patients with FN experienced their first episode in cycle 1
(24/81 [30%]). In the R-CHOP-21 group, approximately
half of the patients with FN experienced their first episode
in cycle 1 (63/133 [47%]).
Baseline demographics and disease characteristics are
summarized by R-CHOP regimen and FN group in Table 1.
As expected, patients who experienced FN generally
exhibited more risk factors for FN.
Chemotherapy dose delays and dose reductions are
presented in Fig. 1. Delays of >3 days were more frequent
in patients who experienced FN than in patients who did
not experience FN for both R-CHOP-14 (75% [95% CI 65–
83%] versus 45% [40–51%]) and R-CHOP-21 (55% [46–
63%] versus 40% [36–44%]). Dose reductions were similar
between FN and no FN patients in the R-CHOP-14 group,
but differences were more prominent in the R-CHOP-21
group (30% [23–38%] versus 18% [15–21%]).
Consequently, fewer patients experiencing FN achieved
RDI ≥90%. In the R-CHOP-14 group, only 37% (27–48%)
of patients who experienced FN achieved RDI ≥90%; in the
R-CHOP-21 group, RDI ≥90% was achieved by 62% (54–
70%) of patients who experienced FN. In contrast, for both
regimens, RDI ≥90% was achieved by over 70% of patients
who did not experience FN (R-CHOP-14, 71% [66–76%];
R-CHOP-21, 76% [73–80%]).
For both R-CHOP regimens, unplanned hospitalizations
occurred in approximately 80% of patients who experi-
enced FN and 20% of patients who did not experience FN
(R-CHOP-14—63/81, 78% [95% CI 68–86%] versus 68/
328, 21% [17–26%]; R-CHOP-21—105/133, 79% [71–
85%] versus 100/569, 18% [15–21%]). Among patients
experiencing FN, mean (±SD) duration of hospitalization
was 12.9 (±16.5) days for patients receiving R-CHOP-14
and 9.6 (±16.5) days for those receiving R-CHOP-21. Mean
duration of hospitalization was approximately 10 days for
patients not experiencing FN (R-CHOP-14, 10.4 [±13.2]
days; R-CHOP-21, 9.8 [±9.1] days). Febrile neutropenia/
neutropenic event was the most common reason for
unplanned hospitalizations among patients who experi-
enced FN (R-CHOP-14, 75 of 118 hospitalizations [64%];
R-CHOP-21, 132/192 [69%]). Nonhematological adverse
event was the most common reason among patients who
did not experience FN (R-CHOP-14, 37/82 [45%]; R-
CHOP-21, 51/132 [39%]).
Discussion
Patients with DLBCL are routinely treated with R-CHOP.
This myelotoxic regimen often results in FN, unplanned
hospitalizations, and impaired chemotherapy delivery [16].
This analysis from a large observational study provides
additional data regarding the impact of FN on chemother-
apy delivery and hospitalizations among patients with
DLBCL receiving R-CHOP-14 or R-CHOP-21.
In this study of clinical practice, around 20% of patients
receiving R-CHOP-14 and R-CHOP-21 experienced FN.
Furthermore, many patients experienced FN during cycle 1,
a finding consistent with previously published data. In a
recent retrospective Spanish study of FN management
among cancer patients treated with cytotoxic chemotherapy,
almost half of all FN events occurred in cycle 1 [13].
Similarly, US studies have reported cycle 1 FN rates of 28–
58% among NHL patients [2, 4, 5, 12, 19]. This high
incidence of cycle 1 FN suggests that secondary prophy-
laxis G-CSF may not be the best approach for managing
chemotherapy-induced FN and provides evidence that FN
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Fig. 1 Dose delays of >3 days in patients who received at least two
chemotherapy cycles, dose reductions of ≥10% in cyclophosphamide
or doxorubicin in any cycle, and patients achieving RDI ≥90%. For
dose delays, superscript a, N=80; superscript b, N=325; superscript c,
N=128; superscript d, N=563
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While over half of patients receiving R-CHOP-21
exhibited multiple risk factors for FN, only 36% of patients
receiving this regimen received PP G-CSF. Moreover, a
small number of patients experiencing FN exhibited none
of the known risk factors, suggesting that additional, as yet
unidentified, risk factors for FN may exist. Notably, only
84% of patients receiving R-CHOP-14 received PP G-CSF,
despite international guidelines recommending PP G-CSF
to support dose dense regimens [1, 18]. For both R-CHOP-
14 and R-CHOP-21, the demographics and baseline disease
characteristics of patients in the FN and no FN subgroups
were markedly different, with patients experiencing FN
more likely to have multiple risk factors for FN. This
suggests that assessing known risk factors for FN before the
first chemotherapy cycle may help clinicians better identify
patients at high risk of FN.
Patients experiencing FN were more likely to receive
suboptimal chemotherapy RDI and to require unplanned
hospitalization. Such reduced chemotherapy delivery has
been associated with impaired outcomes and significantly
decreased survival in patients with NHL [16, 20].
Furthermore, FN-related hospitalizations incur high eco-
nomic costs, with duration of stay an important factor [8–
11, 13]. In the current analysis, mean stays of 9–13 days
were observed, consistent with mean stays of 10.3 and
10.7 days observed in patients with lymphoma and NHL [8,
13]. Two recent studies of the burden of FN management in
Spain and France reported mean medical costs of €4,514
and €4,931 per FN-related hospitalization [6, 13]. Attention
to G-CSF PP in accordance with international guidelines
may help to prevent FN, with the cost of growth factors
being at least partially offset by reduced hospitalization. In
addition to the economic burden, FN-related hospitaliza-
tions are associated with overall inpatient mortality rates of
8–14%, with mortality rates of 21–40% observed among
patients with documented infections [8, 10].
Our findings are strengthened by the fact that this was a
large population representative of clinical practice. However,
since no data regarding the timing of chemotherapy delivery
and hospitalizations in relation to FN episodes are available, a
causal link between FN and these outcomes could not be
established in this study. In conclusion, this analysis demon-
strates that in patients with DLBCL treated with R-CHOP-14
orR-CHOP-21,patientswithaneventofFNweremorelikely
to experience suboptimal chemotherapy delivery and
increased unplanned hospitalizations than those without FN.
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